Clinical Trials Directory

Trials / Completed

CompletedNCT02348385

Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers

Status
Completed
Phase
Study type
Observational
Enrollment
49 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The goal is to examine sex differences in amphetamine-induced dopamine release in tobacco smokers and nonsmokers.

Detailed description

Aim 1: To determine sex differences in amphetamine-induced dopamine (DA) release in healthy tobacco smokers and nonsmokers. FLB-457 has been used in several PET centers and has recently been approved for use at the Yale University PET Center. We would like to determine whether there are sex differences in amphetamine induced DA release in healthy tobacco smokers and nonsmokers. Specifically, 40 healthy tobacco smokers and 40 healthy nonsmokers will have an magnetic resonance imaging (MRI) scan followed on another day by two FLB scans (ideally, the two PET scans will be carried out in the same day). Starting at 3 hours before the second PET scan, amphetamine (0.4mg/kg, PO) will be administered. Aim 2: To determine sex differences in amphetamine-induced dopamine release in tobacco smokers from Aim 1 after treatment with guanfacine. Guanfacine will be given under a different protocol. We plan to determine whether guanfacine treatment differentially inhibits amphetamine-induced DA release in men and smokers from Aim 1. After their first scan, the same 40 healthy tobacco smokers from Aim 1 will take guanfacine for 3 weeks under and then will have another set of FLB scans (ideally, the two PET scans will be carried out in the same day). Starting at 3 hours before the second PET scan, amphetamine (0.4mg/kg, PO) will be administered, as before. The sets of scans will be separated by at least 21 days, but due to scheduling and technical difficulties the second set may be scheduled up to 6 weeks after the first set.

Conditions

Interventions

TypeNameDescription
DRUGAmphetamineSubjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.

Timeline

Start date
2012-12-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2015-01-28
Last updated
2023-03-02
Results posted
2020-03-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02348385. Inclusion in this directory is not an endorsement.